Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.
Sample size justification in phase III/IV clinical trials.
Sarcoma, Avian
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Sample size justification in phase III/IV clinical trials.
Sample size justification in phase III/IV clinical trials. Neuroepidemiology. 1998; 17(2):63-6.
View in:
PubMed
subject areas
Clinical Trials, Phase III as Topic
Clinical Trials, Phase IV as Topic
Epidemiologic Studies
Humans
Research Design
Sample Size
authors with profiles
Sue Leurgans